Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Xiaoyin Bu 1 · Jinman Zhong 1 · Weiru Li 1 · Shengchun Cai 1 · Ya Gao 1 · Baohong Ping 1,2

Received: 3 November 2020 / Accepted: 2 March 2021 / Published online: 11 March 2021
© The Author(s) 2021

Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic strategy to treat several hematological malignancies and non-hematological malignancies. However, graft-versus-host disease (GVHD) is a frequent and serious transplant-related complication which dramatically restrains the curative effect of allo-HSCT and a significant cause of morbidity and mortality in allogeneic HCT recipients. Effective prevention of GVHD mainly depends on the induction of peripheral immune tolerance. Human leukocyte antigen-G (HLA-G) is a non-classical MHC class I molecule with a strong immunosuppressive function, which plays a prominent role in immune tolerance. HLA-G triggers different reactions depending on the activation state of the immune cells and system. It also exerts a long-term immune tolerance mechanism by inducing regulatory cells. In this present review, we demonstrate the immunomodulatory properties of human leukocyte antigen-G and highlight the role of HLA-G as an immune regulator of GVHD. Furthermore, HLA-G could also serve as a good predictor of GVHD and represent a new therapeutic target for GVHD.

Keywords Human leukocyte antigen-G · Immune regulation · Transplantation tolerance · Graft-versus-host disease · Allogeneic hematopoietic stem cell transplantation

Introduction

Allogeneic hematopoietic stem cell transplantation has been widely used in the treatment of various hematological malignancies and non-hematological malignancies, which is one of the most effective treatment options to cure these diseases. Despite the continuous improvement of allo-HSCT, the curative effects and broader application of allo-HSCT are still restricted by graft-versus-host disease, which is an inherent treatment-associated adverse immunologic and life-threatening complication after allo-HSCT, with the incidence up to 40–60% and the mortality approaching 15% [1], becoming a major obstacle to transplantation. During HSCT, conditioning regimen (chemotherapy and/or radiotherapy) could lead to the damage and activation of host tissues and then activate host antigen-presenting cells (APCs) which present host antigens to donor effective T cells, leading to allo-activation and inflammatory cytokine release [2].

Human leukocyte antigen-G (HLA-G) is a functional non-classical human leukocyte antigen class Ib molecule [3]. It is widely acknowledged that HLA-G can interact with inhibitory receptors on T cells, B cells, natural killer (NK) cells, as well as antigen-presenting cells (APCs) and can induce the production of tolerant dendritic cells (tDCs) and regulatory T cells (Tregs), so as to inhibit cellular and humoral immune function and thereby induce immune tolerance [3–7]. HLA-G has attracted an extensive research in the fields of immunology and allogenic hematopoietic stem cell transplantation, in the hope that HLA-G could be used as a diagnostic and/or prognostic marker and potential therapy strategies [8–12].

This review summarized the post-transplantation immune tolerance mediated by HLA-G in GVHD, discussed the role of HLA-G in GVHD, and finally reviewed the therapeutic use of HLA-G in GVHD.
**HLA-G molecules**

Human leukocyte antigen-G (HLA-G) belongs to the non-classical human major histocompatibility complex (MHC) class I b whose gene is located on human chromosome 6p21.3, structurally similar to the classical MHC-I antigen. HLA-G gene is composed of 8 exons separated by 7 introns and selectively cleaved during transcription to produce 7 mature mRNA subtypes, encoding 7 protein isoforms, namely, 4 membrane-bound proteins (HLA-G1, G2, G3, and G4) and 3 soluble proteins (HLA-G5, G6, and G7) [13]. With α1, α2, and α3 domains simultaneously, HLA-G1 and HLA-G5 have the ability to combine with beta-2-microglobulin (β2m) to form HLA-G complexes, with the result that they have biological functions and are the main immunomodulatory subtypes in the HLA-G family [3, 7, 14].

Physiologically, mRNA of HLA-G transcripts is expressed in most cells and tissues, but mature HLA-G has a restricted tissue expression, which is only expressed at a high level in fetal tissues such as the maternal-fetal interface of trophoblast cells, amniotic cells, and erythroid precursor cells, as well as some adult immunity-exempt tissues such as cornea, thymus, and islet cells [3, 15]. It is also expressed in human peripheral blood mononuclear cell and plasma [16, 17]. Pathological conditions such as viral infections, inflammatory diseases, autoimmune diseases, tumors, and allotransplantation can induce the expression of HLA-G [18].

Numerous studies have demonstrated that HLA-G is a very important immune tolerance molecule. It can maintain maternal-fetal immune tolerance at the maternal-fetal interface, reduce inflammation and immune responses, facilitate tumor immune escape, and strengthen transplantation tolerance [7, 19]. Additionally, HLA-G binds to specific receptors to regulate a variety of immune responses and is categorized as a potential “immune checkpoint” molecule [7].

**HLA-G mediates immune regulation**

**Direct regulations of HLA-G on immune cells**

**Effect of HLA-G on T cells**

Both donor CD4+ and donor CD8+ T cells have crucial roles in the pathogenesis of GVHD [20]. Acute GVHD involves alloreactive donor T cell-mediated cytotoxic responses against the tissues of the recipient [20, 21]. Proportions of naive cells maturing along Tregs, Th1, Th2, or Th17 phenotypes have influence on the manifestations and severity of GVHD [2].

CD4+ T cells participate in immune regulation and induce immune tolerance through a variety of immunosuppressive mechanisms, which are the key regulator of the autoimmune response and the inflammatory response. HLA-G interacts with ILT-2 receptors expressed on the surface of CD4+T cells, transduces inhibitory signals, prevents the migration of CD4+ T cells from G1 phase to G2/M phase, and inhibits the proliferation of CD4+T cells, leading CD4+T cells losing their function, thereby inhibiting the function of most T cells. At the same time, it could also induce the transition of cytokine spectrum to Th2 type, producing cytokines such as interleukin (IL)-10 and other cytokines [7, 22]. In addition, soluble HLA-G (sHLA-G) binding to ILT-2 can dramatically downregulate the expression of chemotactic receptors (such as CCR2, CXCR3, and CXCR5) on CD4+T cells and thus CD4+T cells chemotaxis towards CCL2, CCL8, and CXCL10, and CXCL11 is dampened by sHLA-G [23]. CD4+HLA-G+T cells is a novel subset of CD4+Treg cells in human peripheral blood and inflammatory sites. Compared with CD4+CD25+FOXP3+T regulatory cells, CD4+HLA-G+T cells is capable of secreting high levels of soluble HLA-G5 to inhibit the proliferation of allogeneic T cells, secrete higher levels of IL-10, IL-35, and transforming growth factor (TGF)-β1 and other inhibitory factors, and regulate acquired immune response in vivo. It can substantially reduce the severity of acute graft-versus-host disease in humanized mouse model [24, 25].

CD8+T cells are the most toxic killer cells in T cells, which could differentiate into cytotoxic T lymphocytes (CTL) after activation, in turn causing endothelial damage both in the skin and gut, linked to GVHD [12]. HLA-G can inhibit the killing function of alloantigen-specific CTLs by binding to ILT-2 on the surface of CD8+T cells. Similar to classical MHC-I molecules, HLA-G1 and HLA-G5 have the ability to interact with CD8 co-receptor on T cell subsets, activating the Fas/Fas-Ligand-mediated apoptosis in antigen-specific CD8+T lymphocytes [26, 27]. Besides, the expression of CXCR3 on CD8+T cells are notably downregulated by sHLA-G so as to dampen the chemotaxis of CD8+T cells towards CXCL10 and CXCL11, which are the two ligands of CXCR3 [23].

On the other hand, HLA-G can also influence the secretion of cytokines by helper T cells (Th). HLA-G can increase the secretion of Th2 type cytokines such as IL-3, IL-4, and IL-10 while decreasing the secretion of Th1 type cytokines such as interferon (IFN)-γ and tumor necrosis factor (TNF)-α, causing the immune balance shift to Th2 [16]. At the same time, the cytokines secreted by Th2, such as IL-10, can upregulate the expression of HLA-G, so that a positive feedback reaction and a humoral immune response between HLA-G and IL-10 are formed, resulting in a comprehensive and lasting inhibitory effect [16].

**Effect of HLA-G on NK cells**

Natural killer cells are important effector cells of natural immunity [28]. They exert a killing effect by directly dissolving and secreting cytokines and perform a pivotal role in the...
The inhibitory effect of HLA-G on NK cells has been confirmed by extensive studies. In vitro studies have proved that HLA-G presented by target cells (cytotrophoblast cells, tumor cells, transfected cell lines) or soluble HLA-G5 present in microenvironment can inhibit the occurrence of cellular immune synapses of NK cells by binding to ILT2 on the surface of them, thus inhibiting the cytosis of NK cells to target cells [22, 30]. Moreover, HLA-G1 and HLA-G5 have an additive effect on inhibition of NK cell–mediated killing [31]. Additionally, through transferring HLA-G1 and HLA-G3 into human β2m deficient cells, Zhao et al. [32] investigated that β2m-free HLA-G promoted the cytotoxic lysis of NK cells, and meanwhile, the production of proinflammatory cytokines such as IL-1β, TNF-α, and IFN-γ was increased. Morandi et al. [33] revealed that the interaction between soluble HLA-G and ILT2 can downregulate the expression of chemokine receptors (CXCX3 and CD94/NKG2A) on the surface of CD56bright and CD56dim NK cells in peripheral blood and tonsils and, as a result, regulate the chemotaxis of NK cells. Banerjee et al. [34] discovered that the binding of HLA-G to KIR2DL4 on the surface of NK cells does not affect the cytotoxicity of resting NK cells, but can activate NK cells and induce the production of proinflammatory cytokines (such as IFN-γ) and chemokines. However, other studies had found no evidence of functional interaction between sHLA-G and KIR2DL4 in NK cells [35]. Therefore, whether HLA-G/KIR2DL4 interaction affects the activity of NK cells remains controversial [36].

**Effect of HLA-G on APCs**

The activation of antigen-presenting cells plays essential roles in the pathogenesis of GVHD. Dendritic cells (DCs) are the most powerful professional antigen-presenting cells in the body and at the center of initiating, regulating, and maintaining the immune response. Through the release of cytokines, they have the ability to stimulate Th17 responses, thereby initiating and perpetuating GVHD [2]. In vitro, many studies have greatly advanced in the knowledge that HLA-G could inhibit the antigen presentation function of APCs and thus could not effectively stimulate the allogeneic proliferation of T cells [7]. HLA-G can also induce ILT4-mediated inhibitory signal, stimulate downstream IL-6/STAT3 signal pathway, downregulate the expression of MHC-II and costimulatory molecules (CD80 and CD86), block antigen presentation, and thus inhibit the maturation and activation of DC cells, inducing DC cells to differentiate into tolerant DC cells, forming immune tolerance [6, 37]. The mouse experimental model also confirmed that HLA-G could inhibit the maturation and activation of immature DC cells into functional mature DC cells [7]. Moreover, HLA-G can also stimulate APCs to secrete cytokines such as TGF-β and IL-10, so that Th1/Th2 balance shifts to Th2.

**Effect of HLA-G on B cells**

During allogeneic hematopoietic stem cell transplantation, the occurrence of cGVHD is partially owing to the production of autoantibodies [2]. Cognate recognition of foreign MHC II of host B cells by donor alloreactive CD4+T cells has been implicated in cGVHD pathogenesis [2]. Naji et al. [38] found that in a microenvironment rich in IL-10 cytokines, HLA-G can interact with ILT2 on the surface of B cells and thus inhibits the proliferation, differentiation, and immunoglobulin secretion of B cells by means of arresting the cell cycle progression at the G0/G1 phase through PKC phosphorylation and AKT dephosphorylation. Beyond that, HLA-G can also downregulate the expression of B cell chemokine receptors (CXCR4 and CXCR5), thereby inhibiting B cell–mediated chemotaxis [38].

**Indirect regulations of HLA-G on immune system**

**Upregulation of inhibitory receptor expression induced by HLA-G**

The conducted studies have shown that HLA-G can upregulate the expression of self-inhibitory receptors ILT2, ILT4, and KIR2DL4 on the surface of NK cells, APCs, and CD4+T cells, so as to enhance its own inhibitory effect and exert an indirect immunomodulatory effect [10, 39]. Schwich et al. [40] revealed that sHLA-G1 could significantly increase the ILT2 expression of CD8+T cells, while ILT2 on CD4+T cells was only marginally increased. By upregulation of inhibitory receptors, it is able to enhance the sensitivity of HLA-G to immunosuppression and increase the activation threshold of responding cells. At the same time, it may also be a prerequisite for HLA-G-mediated immunosuppression of cells without HLA-G receptor expression.

**HLA-G induces the production of regulatory T cells**

Regulatory T cells are important immune effector cells to promote and maintain peripheral immune tolerance and normal immune homeostasis and play a critical role in transplantation, autoimmune diseases, infection, tumor, and other diseases. It has been demonstrated that HLA-G is capable to stimulate CD4+T cells and CD8+T cells to differentiate into regulatory T cells, thereby inhibiting the reactivity of other T cells [3]. Selmani et al. [41] confirmed that HLA-G5, in vitro, can induce T cells to differentiate into CD4+CD25highFOXP3+Treg cells and regulate the innate immune response. Regulatory T cells can inhibit the immune activity of CD8+CTL and CD4+T cells through cell-to-cell contact or...
production of cytokines such as IL-10 and TGF-β. In addition, HLA-G interacts with ILT2/4 on immature or semi-mature DC cells, activates downstream signaling pathways, and induces the production of tolerant DC cells, which in turn induces the secretion of cytokine IL-10 and differentiation of T cells and can stimulate T cells anergy and inhibit the proliferation of effector T cells [42, 43].

The action mechanism of HLA-G through trogocytosis

Trogocytosis refers to the phenomenon that the cytoplasmic membrane and its related molecules transfer rapidly between cells through cell contact. Through trogocytosis, intact membrane fragments carrying intramembrane and transmembrane proteins can temporarily stay on the surface of the recipient cell, and the cell can temporarily use the proteins it does not express itself and then perform its corresponding function [44]. Studies revealed that through the mechanism of trogocytosis action, T lymphocytes, activated NK cells, and monocytes can obtain HLA-G containing membrane fragments from HLA-G+ antigen-presenting cells or tumor cells. Because the metastatic HLA-G is still functional, T lymphocytes and activated NK cells stop proliferation after receiving the HLA-G membrane fragment and lose their killing ability to the target cells [7]. However, due to the short life span of HLA-G molecules on the surface of monocytes, monocytes do not obtain immunosuppressive function, but can transfer HLA-G membrane fragments obtained from different cell sources together with some of their own membrane fragments to autologous T lymphocytes, thus exerting immune tolerance function [45]. Through the trogocytosis mechanism, the local immunosuppressive effects can occur in the environment where cells expressing HLA-G are scarce.

HLA-G mediates transplantation tolerance

Graft-versus-host disease is a complicated pathological interaction between the innate and adaptive immune systems of the host and donor, including acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD). Among them, acute graft-versus-host disease is an immune-mediated process, in which mature donor T cells interact with host and donor antigen-presenting cells, resulting in the release of proinflammatory cytokines, which leads to the activated T cells proliferating and homing to target tissues, eventually causing damage to host tissues. Unlike aGVHD, which is mainly driven by mature donor T lymphocytes, chronic graft-versus-host disease involves more complex immune responses, which are caused by thymus injury, aberrant B cell production, and T cell dysfunction along with cytokine dysregulation [2, 46, 47]. The entire process involves various immune cell subsets (such as host antigen-presenting cells, effector T cells, and natural killer cells), proinflammatory cytokines (such as TNF-α and IL-1), chemokine and chemokine ligands (such as CCR2 and CCR5), and costimulatory molecules [2, 48].

HLA-G preferentially serves as a ligand for inhibitory HLA-G receptors to exert its immunomodulatory and immunosuppressive properties involved in transplantation tolerance. Meanwhile, inhibitory HLA-G receptors exist on the surface of many kinds of immune cells, such as natural killer cells that express killer cell immunoglobulin-like inhibitory receptor 2DL4 (KIR2DL4) (also known as CD159d) and immunoglobulin-like transmembrane receptor 2 (ILT-2) (also known as CD85j and LILRB1), lymphocytes and granulocyte monocytes express ILT-2, dendritic cells (DCs), and macrophages and monocytes express ILT-4 (also known as CD85d and LILRB2) [40]. By interacting with its cognate receptors of the above immune cell subsets (Fig. 1), HLA-G is able to effectively inhibit the cytolytic activity of NK cells and CD8+ T cells, restrain the allo-proliferative responses of CD4+ T cells, block the progress of allogeneic T cells in the cell-cycle, inhibit the production and activation of antigen-presenting cells, suppress the differentiation and proliferation of B cells, as well as reduce the release of antibody and proinflammatory cytokines, and thus, peripheral immune tolerance is achieved after transplantation and the incidence and severity of GVHD are reduced. Furthermore, HLA-G was shown to indirectly regulate the immune system by inducing regulatory T cells (Tregs) and tolerant dendritic cells (tDCs) to demonstrate a long-term immune tolerance [6, 41]. Such a development of tolerance can be extraordinary beneficial to allo-HSCT, decreasing the rate of aGVHD and cGVHD as well as reducing dependency on immune-suppressive drug regiments.

The role of HLA-G in graft-versus-host disease

Correlation between HLA-G and GVHD

HLA-G was initially detected on the surface of cytrophoblast cells at the maternal-fetal interface and exhibits a crucial role in maternal-fetal tolerance during pregnancy [49]. As a molecule with immunosuppressive function, HLA-G plays a significant role in the development of immune tolerance following transplantation, especially in the field of solid organ transplantation [11]. The expression of HLA-G in heart and kidney transplant patients can reduce the occurrence of transplant rejection [50, 51]. Therefore, the immunoregulatory and immunosuppressive activities of HLA-G have been widely concerned in the development of GVHD after hematopoietic stem cell transplantation in patients with hematologic diseases. In 2008, Le Maux et al. [8] analyzed the soluble HLA-G level in 20 peripheral blood stem cell (PSC)
transplanted patients, showing that sHLA-G molecules play a negative role in the development of aGVHD, and the incidence of aGVHD was low in patients with increased HLA-G expression over time after allo-HSCT, involved specifically in aGVHD prevention. Nomura et al. [12] also draw the similar conclusion that elevated HLA-G/sHLA-G participates in the pathophysiology and prevention of aGVHD following HSCT. Liu et al. [9], through examining the sHLA-G5, sHLA-G6, and sHLA-G7 levels in 106 patients with hematological malignancies before transplantation, on days +15 and +30 after transplantation, revealed that the levels of HLA-G5 were significant lower in patients with grade II–IV aGVHD compared to those with grade 0–I aGVHD, confirming that the increased levels of sHLA-G5 after transplantation were negatively correlated with the severity of aGVHD, and notably, sHLA-G5 rather than sHLA-G6 or sHLA-G7 might predict the development and severity of aGVHD. Biedron et al. [10] also reached a similar conclusion that soluble HLA-G level and HLA-G receptors (ILT2, ILT4, and KIR2DL4) are involved in the intensity of aGVHD and might be a predictor of aGVHD. Kordelas et al. [11] showed that elevated soluble HLA-G levels were not only associated with less severe aGVHD but also with a superior overall survival. They also found that sHLA-G levels were positively relevant to the proportion of regulatory T cells in vivo, and patients with ATG-treated conditioning regimens showed remarkably higher levels of sHLA-G, tempting to speculate that ATG treatment improved the level of sHLA-G via IL-10, which in turns led to the induction and expansion of regulatory T cells. In contrast, Waterhouse et al. [52] carried out research on 59 patients undergoing allo-HSCT and found no correlation between sHLA-G concentration and post-transplantation complications such as aGVHD, cGVHD, relapse, or death. The possible explanation for contradictory conclusions may be HLA disparity, gender mismatching, individual factors, disease status before transplantation, the stem cell dose, conditioning regimen, GVHD prophylaxis, and so on.

The specific implications of soluble human leukocyte antigen-G in the development of GVHD are presented in Table 1.

**Correlation between 14-bp polymorphism and GVHD**

The HLA-G locus is scarcely polymorphic in the coding region, but several genetic variations at the 3′ untranslated region (UTR) have been identified [22]. Previous studies have proposed that the HLA-G mRNA stability and the expression of HLA-G are related to 14-base pair (bp) insertion/deletion (ins/del) polymorphism in exon 8 in the 3′ UTR of the HLA-G gene. Chen et al. [53], through genotyping the 14-bp ins/del gene polymorphism and determining the expression of plasma sHLA-G in 150 normal Chinese Han population, found that plasma-soluble HLA-G level with homozygotes for 14-bp del and heterozygotes was dramatically higher than that with the homozygotes for 14-bp ins, whereas there was no remarkable difference between the homozygotes for 14-bp del and
heterozygotes. The same results have been proved in Brazilian and French population [54], and consensually, the 14-bp ins/ins genotype leads to lower HLA-G protein expression [55]. Taking these into consideration, it seems to be implicated that the 14-bp polymorphisms that favor HLA-G expression must be linked to less severe GVHD. In 2011, Boukouaci et al. [56] analyzed HLA-G 14-bp ins/del dimorphism in 157 patients with sibling bone marrow transplantation, in which univariate analysis showed that the homozygotes for 14-bp insertion was correlated with the occurrence of severe aGVHD (grade III and IV), and multivariate analysis further confirmed the correlation, suggesting that the decrease of HLA-G expression caused by 14-bp insertion is a risk factor of severe aGVHD. Other studies have drawn different conclusions. La Nasa et al. [57] investigated 14-bp polymorphism in 53 unrelated donor HSCT for thalassemia and found that homozygote for 14-bp deletion had a higher risk of aGVHD than homozygote for 14-bp insertion. Sizzano et al. [58] did not find that 14-bp ins/ins homozygous patients had a higher risk of severe aGVHD than 14-bp del/del homozygous and 14-bp ins/del heterozygous patients. Waterhouse et al. [52] proved that 14-bp ins/ins patients showed remarkable lower pre-transplantation levels of HLA-G compared to those carrying the 14-bp del/del and 14-bp ins/del genotype, but there was no significant difference between the 3 different genotype groups after HSCT, and the recipients or donor HLA-G 14-bp polymorphism was not associated with the occurrence of aGVHD, cGVHD, relapse, or death. Although there was no association between 14-bp genotype polymorphisms and aGVHD, Chiusolo et al. [59] observed that 14-bp ins/del and 14-bp del/del patients were characterized by a higher OS and DFS. The reasons for the controversial results about the correlation between 14-bp polymorphism and GVHD are as follows: firstly, HLA-G molecules have ethnical differences; secondly, the incidence of HLA-G 14-bp polymorphisms in the general population is different; thirdly, the HLA system is complex; fourthly, the screening conditions of each research center are different; and last but not least, a large cohort of patients should be performed to further confirm the present results. Therefore, further studies need to be performed to investigate whether HLA-G polymorphism could result in the occurrence of GVHD by affecting the level of HLA-G.

The specific implications of 14-bp polymorphism in the occurrence of GVHD are listed in Table 2.

### Table 1: Results of correlation between HLA-G and GVHD

| Study            | N   | Role in GVHD                                                                 |
|------------------|-----|-----------------------------------------------------------------------------|
| Le Maux et al.   | 20  | Soluble HLA-G level was significantly higher before transplantation and post-allograft period of without aGVHD patients compared with aGVHD patients. sHLA-G molecules could be involved in aGVHD prevention |
| Nomura et al.    | 135 | Elevated HLA-G/shHLA-G participates in the pathophysiology and prevention of aGVHD |
| Liu et al.       | 106 | The increased levels of sHLA-G after transplantation were negatively correlated with the severity of aGVHD. sHLA-G5 might predict the occurrence and severity of aGVHD |
| Biedron et al.   | 32  | Soluble HLA-G level was related to intensity of GVHD and may play the role of a prognostic factor for the development of GVHD and the clinical course of this reaction |
| Kordelas et al.  | 32  | Elevated sHLA-G levels were correlated with less severe acute and chronic GVHD and with a superior overall survival |
| Waterhouse et al. | 59  | Soluble HLA-G concentration had no correlation between post-transplantation complications such as aGVHD, cGVHD, relapse, or death |

### HLA-G as a potential biologic immunosuppressant for GVHD

Mesenchymal stem cells (MSC) are adult stem cells that exist in many kinds of tissues, such as bone marrow, umbilical cord placenta, and adipose tissue, which have the functions of multi-directional differentiation, immune regulation, supporting hematopoiesis, and tissue repair and have been extensively used in the treatment of regenerative medicine and autoimmune diseases. Since Le Blanc et al. [60] first reported the striking results of MSC used in a patient with severe treatment-resistant grade IV aGVHD, MSC has become an alternative cell therapy, which is commonly used in the second-line treatment of aGVHD [61]. Studies have observed that HLA-G5 was expressed in mesenchymal stem cells, and it mediated the modulation of immune response by MSC [41, 62]. Moreover, data showed that MSC\(^{HLA-G+}\) had better immunosuppressive functions than do MSC\(^{HLA-G+/−}\), enhancing inhibition of allogeneic T cell proliferation in vitro. The above data are in favor of the potential application of HLA-G5 combined with MSC as immunosuppressant cells to treat aGVHD. Kordelas et al. [63] demonstrated that the application of MSC-derived exosomes containing high concentrations of HLA-G in a patient with steroid-refractory severe acute GVHD has led to a remarkable improvement in GVHD symptoms. Collectively, HLA-G could be a specific marker for therapeutic approaches using MSCs or MSC-derived exosomes to treat therapy-refractory aGVHD.
It is widely recognized that regulatory T cells immunotherapy can suppress exuberant immune system activation and promote immunologic tolerance. Numerous studies have shown that Tregs can be used to the prevention and treatment of aGVHD. Edinger et al. [64] showed that adoptive infusion of Tregs after allo-HSCT can prevent the occurrence of aGVHD, which is helpful to immune reconstruction mediated by conventional T cells after transplantation and, meanwhile, retain the graft-versus-leukemia (GVL) effect [65]. However, the low numbers of Tregs in the circulation and Treg stability would affect the therapeutic effect [65, 66]. Stamou et al. [65] exposed human peripheral blood T cells to azacytidine/decitabine to induce the generation of CD4+HLA-G+FOXP3-T cells, which was a stable Treg subset and showed potent suppression function in vitro. Taking these into account, it could be hypothesized that hypomethylating agents-induced CD4+HLA-G+FOXP3-T cells in vitro would be adoptive cellular immunotherapy against acute graft-versus-host disease. On the other hand, Favier et al. [67] injected with B2M-associated HLA-G5-coated beads into skin allograft recipient mice and demonstrated the tolerogenic function of B2M-HLA-G5 dimers in the context of skin allograft transplantation. LeMaoult et al. [68] also showed that synthetic HLA-G proteins could be therapeutic use in transplantation.

For the above available data along with the proved transplantation tolerance induced by HLA-G and the relationship between HLA-G levels and GVHD, therapeutic HLA-G molecules have been proposed as a promising and ideal biologic immunosuppression candidate for clinical use to the prevention and treatment of GVHD. However, with the problems of structure and lack of a stable purified molecule, the clinical use of HLA-G molecules as therapeutic agents faces several hindrances. Future development will optimize the synthesis of stable HLA-G proteins and then evaluate its ability in vivo as a recombinant molecule alone or in combination with immunosuppressant drugs to prevent and/or treat GVHD. In addition, the use of mesenchymal stem cells or regulatory T cells that express or secrete HLA-G to prevent and/or treat GVHD is a promising strategy in the future, which could improve the clinical outcomes of patients.

**Conclusion and perspectives**

Graft-versus-host disease is the most common serious complication after allogeneic hematopoietic stem cell transplantation. Revealing the mechanism of GVHD and then guiding the prevention even the treatment of GVHD has become widely concerned and studied. Studies have confirmed that HLA-G can directly interact with immune cells and inhibit the cellular and humoral immune function of the body, thus contributing to induce immune tolerance and reduce the incidence of GVHD. Continuing and in-depth understanding the role of HLA-G in immune regulation and in the context of graft-versus host disease could not only develop the basic theory of immunology but also have the potential to open up new avenues for clinical diagnosis, prognosis evaluation, as well as providing a new direction for the treatment of GVHD.

**Author contribution** Xiaoyin Bu wrote the original manuscript, Ya Gao reviewed and edited the manuscript, and Baohong Ping provided overall guidance. Jinman Zhong, Weiru Li, and Shengchun Cai collected and organized the literature.

**Funding** The authors are indebted to gratefully acknowledge Natural Science Foundation of China (81701243, 81870145), Science and Technology Planning Project of Guangzhou (201904010481), Natural Science Fundation of Guangdong Province(2020A1515010038), Presidential Foundation of Nanfang Hospital of Southern Medical University (No. 2017C030), and Presidential Foundation of Zhujiang Hospital of Southern Medical University (No. yzjj2018rc03).

**Declarations**

**Ethics approval** This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of interest  The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Rodrigues KS, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R (2018) Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol 19(1):33–50. https://doi.org/10.1007/s40257-017-0306-9

2. Zhang L, Chu J, Yu J, Wei W (2016) Cellular and molecular mechanisms in graft-versus-host disease. J Leukoc Biol 99(2):279–287. https://doi.org/10.1189/jlb.0615-254RR

3. Curigliano G, Criscitiello C, Gelao L, Goldhirsch A (2013) Molecular pathways: human leukocyte antigen G (HLA-G). Clin Cancer Res 19(20):5564–5571. https://doi.org/10.1158/1078-0432.CCR-12-13697

4. Morandi F, Rizzo R, Fainardi E, Rouas-Freiss N, Pistoia V (2016) Recent advances in our understanding of HLA-G biology: lessons from a wide spectrum of human diseases. J Immunol Res 2016:1–14. https://doi.org/10.1155/2016/4326495

5. Amadio G, Comi M, Tomasoni D, Gianolini ME, Rizzo R, LeMaoult J, Roncarolo MG, Gregori S (2015) HLA-G expression levels influence the tolerogenic activity of human DC-10. Haematologica 100(4):548–557. https://doi.org/10.3324/haematol.2014.113803

6. Gregori S, Tomasoni T, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, Hauben E, Roncarolo MG (2010) Differentiation of Type I T Regulatory Cells (Tr1) by Tolerogenic DC-10 Requires the IL-10-dependent ILT4/HLA-G Pathway. Blood 116(6):935–944. https://doi.org/10.1182/blood.2009-07-234872

7. Carosella ED, Rouas-Freiss N, Roux DT, Moreau P, LeMaoult J (2015) HLA-G: An immune checkpoint molecule. Adv Immunol 127:33–144. https://doi.org/10.1016/bs.ai.2015.04.001

8. Le Maux A, Noël G, Birebent B, Grosset J, Vu N, De Guibert S et al (2008) Soluble human leukocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells. Clin Exp Immunol 152(1):50–56. https://doi.org/10.1111/j.1365-2249.2008.03598.x

9. Liu H, Chen Y, Xuan L, Wu X, Zhang Y, Fan Z, Huang F, Zhang X, Jiang Q, Sun J, Liu Q (2013) Soluble human leukocyte antigen g molecule expression in allogeneic hematopoietic stem cell transplantation: good predictor of acute graft-versus-host disease. Acta Haematol 130(3):160–168. https://doi.org/10.1159/000350488

10. Biedroń M, Rybka J, Wrobel T, Prjas I, Poreżka R, Kuliżewski K (2015) The role of soluble HLA-G and HLA-G receptors in patients with hematological malignancies after allogeneic stem cell transplantation. Med Oncol 32:219. https://doi.org/10.1007/s12032-015-0664-1

11. Kordelas L, Da Silva NF, Wagner B, Ditschkowski M, Liebregts T, Lindemann M et al (2018) Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease. Bone Marrow Transplant 53(9):1149–1156. https://doi.org/10.1038/s41409-018-0145-1

12. Nomura S, Ito T, Katayama Y, Ota S, Hayashi K, Fujitsu S, Satake A, Ishii K (2019) Effects of recombinant thrombomodulin therapy and soluble human leukocyte antigen-G levels during hematopoietic stem cell transplantation. Transpl Immunol 53:28–33. https://doi.org/10.1016/j.trimat.2018.12.001

13. Donadi EA, Castelli EC, Arauza-Villena A, Roger M (2011) Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci 68(3):369–395. https://doi.org/10.1007/s00018-010-0580-7

14. Pistoia V, Morandi F, Wang X, Ferrone S (2007) Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 17(6):469–479

15. Bai Y, Liang J, Liu W, Wang F, Li C (2020) Possible roles of HLA-G regulating immune cells in pregnancy and endometrial diseases via KIR2DL4. J Reprod Immunol 142:10176. https://doi.org/10.1016/j.repi.2020.103176

16. Li X, Sheng Z, Sun Y, Wang Y, Xu M, Zhang Z et al (2018) Human leukocyte antigen-G upregulates immunoglobulin-like transcripts and corrects dysfunction of immune cells in immune thrombocytopenia. Haematologica 2020:204040–204781. https://doi.org/10.3324/haematol.2018.204040

17. Rebmann V, Busemann A, Lindemann M, Grosse-Wilde H (2003) Detection of HLA-G5 secreting cells. Hum Immunol 64(11):1017–1024. https://doi.org/10.1016/j.humimm.2003.08.354

18. Lazarte J, Adamson MB, Tumiati LC, Delgado DH (2018) 10-year experience with HLA-G in heart transplantation. Hum Immunol 79(8):587–593. https://doi.org/10.1016/j.humimm.2018.05.003

19. González A, Rebmann V, LeMaoult J, Horn PA, Carosella ED, Alegre E (2012) The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci 49(3):63–84. https://doi.org/10.3109/10408636.2012.677947

20. Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12(6):443–458. https://doi.org/10.1038/nnm3212

21. Li A, Abraham C, Wang Y, Zhang Y (2020) New insights into the basic biology of acute graft-versus-host-disease. Haematologica 105(11):2540–2549. https://doi.org/10.3324/haematol.2019.240291

22. Amadio G, Sales DAR, Gregori S (2014) New insights into HLA-G mediated tolerance. Tissue Antigens 84(3):255–263. https://doi.org/10.10111/j.tan.2014.03.002

23. Morandi F, Ferretti E, Bocca P, Prigione I, Raffaghello L, Pistoia V (2010) A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T Cell chemokine receptor expression and impairment of chemotaxis. PLoS One 5(7):e11763. https://doi.org/10.1371/journal.pone.0017163

24. Pankratz S, Bittner S, Herrmann AM, Schulmann MK, Ruck T, Meuth SG et al (2016) CD4+HLA-G+ regulatory T cells: molecular signature and pathophysiological relevance. Hum Immunol 77(9):727–733. https://doi.org/10.1016/j.humimm.2016.01.016

25. Pankratz S, Bittner S, Herrmann AM, Schulmann MK, Ruck T, Meuth SG, Wiendl H (2014) Human CD4+HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo. FASEB J 28(8):3435–3445. https://doi.org/10.1096/fj.14-251074

26. Rebmann V, Nardi FDS, Wagner B, Horn PA (2014) HLA-G as a tolerogenic molecule in transplantation and pregnancy. J Immunol Res 2014:297016. https://doi.org/10.1155/2014/297073

27. Contini P, Ghio M, Merlo A, Poggi A, Indiveri F, Puppo F (2005) Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and Calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation. J
28. Chen Y, Lu D, Churuv A, Fu R (2020) Research progress on NK cell receptors and their signaling pathways. Mediat Inflamm 2020:6437057–6437014. https://doi.org/10.1155/2020/6437057
29. Zagh E, Calvi M, Marcenaro E, Mavilio D, Di Vito C (2019) Targeting NKGA2 to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy. J Leukoc Biol 105(6):1243–1251. https://doi.org/10.1002/jlb.MR0718-300R
30. Schmitt J, Eckardt S, Schlegel PG, Sirén A, Bruttel VS, McLaughlin KJ et al (2015) Human pathogenetic embryonic stem cell-derived neural stem cells express HLA-G and show unique resistance to NK cell-mediated killing. Mol Med 21(1):185–196. https://doi.org/10.2191/molmed.2014.00188
31. Zhang W, Xu D, Liu D, Li Y, Ruan Y, Lin A et al (2014) HLA-G1 and HLA-G5 isoforms have an additive effect on NK cytolysis. Hum Immunol 75(2):182–189. https://doi.org/10.1016/j.humimm.2013.11.001
32. Zhao L, Purandare B, Zhang J, Hantash BM (2013) β2-Microglobulin-free HLA-G activates natural killer cells by increasing cytotoxicity and proinflammatory cytokine production. Hum Immunol 74(4):417–424. https://doi.org/10.1016/j.humimm.2012.11.022
33. Morandi F, Ferretti E, Castriconi R, Dondero A, Petretto A, Bottino C, Pistoia V (2011) Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood 118(22):5840–5850. https://doi.org/10.1182/blood-2011-06-424915
34. Banerjee PP, Pang L, Soldan SS, Miah SM, Eisenberg A, Maru S, Waldman A, Smith EA, Rosenberg-Hasson Y, Hirschberg D, Smith A, Ablashi DV, Campbell KS, Orange JS (2014) Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood 118(22):5840–5850. https://doi.org/10.1182/blood-2011-06-424915
35. Le Page MEL, Goodridge JP, John E, Christiansen FT, Witt CS (2014) Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-γ responses to soluble HLA-G preparations. J Immunol 192(2):732–740. https://doi.org/10.4049/jimmunol.1301748
36. Silva ILD, Montero-Montero L, Ferreira E, Quintanilla M (2018) New insights into the role of Qa-2 and HLA-G Non-classical MHC-I complex genes in malignancy. Front Immunol 9:2894. https://doi.org/10.3389/fimmu.2018.02894
37. Liang S, Ristic V, Arase H, Dausset J, Carosella ED, Horuzsko A (2008) Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6–STAT3 signaling pathway. Proc Natl Acad Sci U S A 105(24):8357–8362. https://doi.org/10.1073/pnas.0803341105
38. Naji A, Menier C, Morandi F, Agaugué S, Maki G, Ferretti E, Bruel S, Pistoia V, Carosella ED, Rouas-Freiss N (2014) Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol 192(4):1536–1546. https://doi.org/10.4049/jimmunol.1300438
39. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED, Rouas-Freiss N, Moreau P, Donadi EA (2013) Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential Hla-G soluble Levels in the plasma of allogeneic hematopoietic cell transplantation. Transplant Proc 45(1):397–401. https://doi.org/10.1016/j.transproceed.2012.05.073
40. Chen XY, Yan WH, Lin A, Xu HH, Zhang JG, Wang XX (2008) The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. Tissue Antigens 72(4):335–341. https://doi.org/10.1111/j.1399-0039.2008.01073.x
41. Martelli-Palomino G, Pancotto JA, Muniz YC, Mendes-Junior CT, Castelli EC, Masaro JD, Krawicz-Radame I, Portas I, Rebmann V, Carosella ED, Rouas-Freiss N, Moreau P, Donadi EA (2013) Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential Hla-G soluble Levels in the Brazilian and French population. PLoS One 8(10):e71742. https://doi.org/10.1371/journal.pone.0071742
high, normal and low soluble HLA-G expression. Hum Immunol 74(2):203–206. https://doi.org/10.1016/j.humimm.2012.10.027

56. Boukouaci W, Busson M, Fortier C, Amokrane K, de Latour RP, Robin M, Krishnamoorthy R, Toubert A, Charron D, Socié G, Tamouza R (2011) Association of HLA-G low expressor genotype with severe acute graft-versus-host disease after sibling bone marrow transplantation. Front Immunol 2:74. https://doi.org/10.3389/fimmu.2011.00074

57. La Nasa G, Littera R, Locatelli F, Lai S, Alba F, Caocci G et al (2007) The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. Br J Haematol 139(2):284–288. https://doi.org/10.1111/j.1365-2141.2007.06779.x

58. Sizzano F, Testi M, Zito L, Crocchiolo R, Troiano M, Mazzi B, Turchiano G, Torchio M, Pultrone C, Gregori S, Chiesa R, Gazzè I, Sodani P, Marktel S, Amoroso A, Roncarolo MG, Lucarelli G, Andreani M, Fleischhauer K (2012) Genotypes and haplotypes in the 3' untranslated region of the HLA-G gene and their association with clinical outcome of hematopoietic stem cell transplantation for beta-thalassemia. Tissue Antigens 79(5):326–332. https://doi.org/10.1111/j.1399-0039.2012.01862.x

59. Chiusolo P, Bellesi S, Piccirillo N, Giammarco S, Marietti S, De Ritis D et al (2012) The role of HLA – G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis. Bone Marrow Transplant 47(1):120–124. https://doi.org/10.1038/bmt.2011.40

60. Le Blanc K, Rasmussen I, Sundberg B, Götherström C, Hassan M, Uzunel M et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439–1441. https://doi.org/10.1016/S0140-6736(04)6104-7

61. Yi HG, Yang S, Kim I, Lee J, Min C, Kim JH et al (2016) Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Korean J Physiol Pharmacol 20(1):63–67. https://doi.org/10.4196/kjpp.2016.20.1.63

62. Deschaseaux F, Gaillard J, Langonné A, Chauveau C, Naji A, Bouacida A, Rosset P, Heymann D, de Pinieux G, Rouas-Freis N, Senséb L (2013) Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue. FASEB J 27(8):2977–2987. https://doi.org/10.1096/fj.13-227264

63. Kordelas L, Rebmann V, Ludwig A, Radtke S, Ruesing J, Döppner TR et al (2014) MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28(4):970–973. https://doi.org/10.1038/leu.2014.41

64. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS (2003) CD4+CD25+ regulatory T cells preserve graft-versus- tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9(9):1144–1150. https://doi.org/10.1038/nm915

65. Stamou P, Marioli D, Patmanidi AL, Sgourou A, Vittoraki A, Theofani E, Plerides C, Taraviras S, Costeas PA, Spyridonidis A (2017) Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease. Cytotherapy 19(4):521–530. https://doi.org/10.1016/j.jcyt.2017.01.004

66. Lam AJ, Hoeppli RE, Levings MK (2017) Harnessing advances in T regulatory cell biology for cellular therapy in transplantation. Transplantation 101(10):2277–2287. https://doi.org/10.1097/TP.0000000000001757

67. Favier B, HoWangYin K, Wu J, Caumartin J, Daouya M, Hortuzsko A et al (2011) Tolerogenic function of dimeric forms of HLA-G recombinant proteins: a comparative study in vivo. PLoS One 6(7):e21011. https://doi.org/10.1371/journal.pone.0021011

68. LeMaoult J, Daouya M, Wu J, Loustau M, Horuzsko A, Carosella ED (2013) Synthetic HLA-G proteins for therapeutic use in transplantation. FASEB J 27(9):3643–3651. https://doi.org/10.1096/fj.13-228247

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.